Results 321 to 330 of about 1,804,185 (380)

Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody

Mahomed S, Mkhize NN, Serebryannyy LA, Hermanus T, Kgagudi P, Kaldine H, Lambson B, Narpala SR, Basappa M, Castro M, Lin BC, Carlton K, Sands JT, Gall JG, Koup RA, Morris L, Karim QA, Moore PL, Karim SA, Doria-Rose N.   +19 more
europepmc   +1 more source

Leveraged Vaccination to Alleviate Original Antigenic Sin for Enhancing Broad-Neutralizing Antibody Response against SARS-CoV-2 Omicron Subvariants. [PDF]

MedComm (2020)
Zhang G, Wang Q, Ji K, Wang Y, Xu W, Zhou J, Liu Z, Xiu R, Xing L, Zhou J, Shi Y, Lu X, Wang X, Ying B, Lu L, Jiang S.   +15 more
europepmc   +1 more source

FMO2 Promotes Angiogenesis via Regulation of N‐Acetylornithine

Advanced Science, EarlyView.
This study identifies flavin‐containing monooxygenase 2 (FMO2) as a novel proangiogenic regulator in endothelial cells. Targeted FMO2 ablation impairs vessel sprouting, whereas its compensation potently enhances angiogenesis. Metabolomics and single‐cell sequencing reveal that FMO2 drives vascular growth via the N‐acetylornithine/ATF3/NOTCH1 axis ...
Jingyi Wang, Yinghui Xu, Xianpeng Wu, Mo Li, Changchen Xiao, Zaiyang Fu, Yongjian Chen, Qingju Li, Yating Ruan, Jing Zhao, Zhiwei Zhong, Jinghai Chen, Wei Zhu, Jinliang Nan, Cheng Ni, Xinyang Hu   +15 more
wiley   +1 more source

A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV. [PDF]

Structure
Sajadi MM, Abbasi A, Tehrani ZR, Siska C, Clark R, Chi W, Seaman MS, Mielke D, Wagh K, Liu Q, Jumpa T, Ketchem RR, Nguyen DN, Tolbert WD, Pierce BG, Atkinson B, Deming D, Sprague M, Asakawa A, Ferrer D, Dunn Y, Calvillo S, Yin R, Guest JD, Korber B, Mayer BT, Sato AH, Ouyang X, Foulke S, Habibzadeh P, Karimi M, Aslanabadi A, Hojabri M, Saadat S, Zareidoodeji R, Kędzior M, Pozharski E, Heredia A, Chen H, Montefiori D, Ferrari G, Pazgier M, Lewis GK, Jardine JG, Lusso P, DeVico A.   +45 more
europepmc   +1 more source

Developing a Personalized Cancer Nanovaccine Using Coxsackievirus‐Reprogrammed Cancer Cell Membranes for Enhanced Anti‐Tumor Immunity

Advanced Science, EarlyView.
A personalized nanovaccine combining PLGA‐encapsulated heat‐inactivated CVB3 and membranes from CVB3‐infected breast cancer cells stimulates potent antitumor immunity. It reduces immunosuppressive markers, enhances immune activation, and improves survival in vivo.
Amirhossein Bahreyni, Yasir Mohamud, Amrit Singh, Razieh Sadat Banijamali, Jeffrey Tang, Jingchun Zhang, Honglin Luo   +6 more
wiley   +1 more source

Epitope mapping of a neutralizing antibody against rabbit hemorrhagic disease virus GI.2. [PDF]

Vet Res
Podadera A, Leuthold M, Martín-Alonso JM, Casais R, Álvarez AL, Lobo-Castañón MJ, Parra F, Dalton KP.   +7 more
europepmc   +1 more source

PD‐L1‐Targeting Biomimetic Photoresponsive Thermosensitive Liposomes for Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
Tan et al. developed a platelet membrane‐coated, thermoresponsive liposome for targeted, light‐controlled delivery of fluorinated peptides that promotes programmed death‐ligand 1 degradation, induces tumor immunogenic cell death, suppresses solid tumors and metastases, and triggers durable immune memory, offering a promising strategy for peptide‐based ...
Manman Tan, Chengyu Shi, Guangyi Chi, Xinwan Su, Fangzhou Liu, Linyu Zhu, Guangqian Cheng, Xiangyi Chen, Meng Yu, Yijian Chen, Ying Wang, Yu Chen, ShuLing Yan, Wenfei Wu, Qingfeng Yan, Jianzhong Shao, Kai Wang, Xiangrui Liu, Min Zhou, Aifu Lin   +19 more
wiley   +1 more source

Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort study. [PDF]

PLOS Glob Public Health
Mkhize NN, Li SS, Hu J, Robinson ST, Hoosain Z, Garrett N, Chirenje ZM, Fleurs L, Kaldine H, Modise T, Moore PL, Randhawa AK, Sholukh AM, Hutter J, Polakowski L, Corey L, Gill K, Montefiori DC, Janes H, Karuna S, HVTN 405/HPTN 1901 Study Team.   +20 more
europepmc   +1 more source

Type specificity of complement-requiring and immunoglobulin M neutralizing antibody in initial herpes simplex virus infections of humans

, 1975
Nathalie J. Schmidt, Bagher Forghani, E. H. Lennette   +2 more
openalex   +1 more source

FGF9–FGFR2 Signaling via Osteocytes‐Preosteoblasts Crosstalks to Mediate Mechanotransduction‐Driven Intramembranous Osteogenesis in the Underdeveloped Maxilla

Advanced Science, EarlyView.
This study identifies osteocyte‐derived FGF9 as a mechanosensitive factor that impairs osteogenesis in the underdeveloped maxilla by inducing FGFR2 nuclear translocation in preosteoblasts. Mechanical stimulation reduces FGF9 secretion, relieving its inhibitory effect. These findings reveal a novel osteocyte–preosteoblast FGF9–FGFR2 axis in craniofacial
Yiwen Zhou, Lili Chen, Miaomiao Han, Peixiang Zhu, Yanyi Wang, Xuanxuan Yu, Tingyu Reng, Huijuan Wang, Baochao Li, Caixia Zhang, Ziwei Huang, Shuang Lin, Guoyun Wang, Jie Ge, Baosheng Guo, Huang Li   +15 more
wiley   +1 more source